Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial

The integrity of retinal ganglion cells is tightly associated with diabetic macular degeneration that leads to damage and death of retinal ganglion cells,affecting vision.The major clinical treatments for diabetic macular edema are anti-vascular endothelial growth factor drugs and laser photocoagulation.However,although the macular thickness can be normalized with each of these two therapies used alone,the vision does not improve in many patients.This might result from the incomplete recovery of retinal ganglion cell injury.Therefore,a prospective,non-randomized,controlled clinical trial was designed to investigate the effect of anti-vascular endothelial growth factor drugs combined with laser photocoagulation on the integrity of retinal ganglion cells in patients with diabetic macular edema and its relationship with vision recovery.In this trial,150 patients with diabetic macular edema will be equally divided into three groups according to therapeutic methods,followed by treatment with anti-vascular endothelial growth factor drugs,laser photocoagulation therapy,and their combination.All patients will be followed up for 12 months.The primary outcome measure is retinal ganglion cell-inner plexiform layer thickness at 12 months after treatment.The secondary outcome measures include retinal ganglion cell-inner plexiform layer thickness before and 1,3,6,and 9 months after treatment,retinal nerve fiber layer thickness,best-corrected visual acuity,macular area thickness,and choroidal thickness before and 1,3,6,9,and 12 months after treatment.Safety measure is the incidence of adverse events at 1,3,6,9,and 12 months after treatment.The study protocol hopes to validate the better efficacy and safety of the combined treatment in patients with diabetic macula compared with the other two monotherapies alone during the 12-month follow-up period.The trial is designed to focus on clarifying the time-effect relationship between imaging measures related to the integrity of retinal ganglion cells and best-corrected visual acuity.The trial protocol was approved by the Medical Ethics Committee of the Affiliated Hospital of Beihua University with approval No.(2023)(26)on April 25,2023,and was registered with the Chinese Clinical Trial Registry(registration number:ChiCTR2300072478,June 14,2023,protocol version:2.0).

Conbercept combined with laser photocoagulation in the treatment of diabetic macular edema and its influence on intraocular cytokines

BACKGROUND The prevalence of diabetes mellitus(DM)in China is high,and the base is broad.Diabetic retinopathy(DR)is a critical condition affecting the life and health of a nation and its economic development.DR is a common complication of DM.AIM To investigate the efficacy of laser photocoagulation combined with intravitreal injection of conbercept for treating macular edema.METHODS Overall,130 patients with diabetic macular edema(DME)hospitalized in The Third People’s Hospital of Changzhou from January 2019 to June 2022 were retrospectively included.According to the treatment plan,130 patients with DME were categorized into an observation and a control group,with 65 patients in each group.The control group received laser photocoagulation,and the observation group received laser photocoagulation with intravitreal injection of conbercept.Observe changes in vision,cytokines in the eye and so on.RESULTS The total efficacy rate in the observation group(93.85%)was higher than that in the control group(78.46%)(P<0.05).In both groups,the best corrected visual acuity correction effect improved after treatment,and the observation group was superior to the control group(P<0.05).Retinal thickness and central macular thickness improved after treatment,and the observation group was superior to the control group(P<0.05).The levels of vascular endothelial growth factor,interleukin-6,soluble intercellular adhesion molecule-1,and basic fibroblast growth factor in both groups improved after treatment,and the observation group was superior to the control group(P<0.05).CONCLUSION In patients with macular edema,combining laser photocoagulation and intravitreal injections of conbercept for DME is a more effective and safer strategy to improve vision,and lower intraocular cytokine levels.

Is laser photocoagulation still effective in diabetic macular edema? Assessment with optical coherence tomography in Nepal

AIM: To find out the outcome of laser photocoagulation in clinically significant macular edema (CSME) by optical coherence tomography (OCT). · METHODS: It was a prospective, non-controlled, case series study enrolling 81 eyes of 64 patients with CSME between August 2008 and January 2010. All patients received modified grid photocoagulation with frequency doubled Nd: YAG laser. Each patient was evaluated in terms of best-corrected visual acuity (BCVA) and regression or progression of maculopathy after laser therapy at 1, 3 and 6 months. Spearman’s correlation test was used to show the correlation between BCVA and total macular volume (TMV). Analysis of variance (ANOVA) was used to compare among groups and independent t-test was used to compare in each group. · RESULTS: There is high correlation between BCVA and TMV (P ≤0.001). BCVA improved in 50.6%, remained static in 39.5 % and deteriorated in 9.9% patients after 6 month of treatment. The Baseline TMV (mean and SD) were 9.26±1.83, 10.4±2.38, 11.5±3.05, 8.89±0.75 and 9.47±1.98 mm3 for different OCT patterns, ST (sponge like thickening), CMO (cystoid macular edema), SFD (subfoveal detachment), VMIA (Vitreo macular interface abnormality) and average TMV respectively (P =0.04). After 6 months of laser treatment, the mean TMV decreased from 9.47±1.98mm3 to 8.77±1.31mm3(P =0.01). In ST there was significant decrease in TMV, P =0.01, Further within these groups at 6 months, they were significantly different, P =0.01. · CONCLUSION: OCT showed the different morphological variant of CSME while the response of treatment is different. TMV decreased the most and hence showed the improvement in vision after 6 months of laser treatment. In the era of Anti vascular endothelial growth factors (VEGFs), efficacy of laser seems to be in shadow but it is still first line of treatment in developing nation like Nepal where antiVEGFs may not be easily available and affordable.

Short-term effects of intravitreal Conbercept injection combined with laser photocoagulation on macular edema secondary to ischemic retinal vein occlusion

AIM:To observe changes in the best-corrected visual acuity(BCVA),central macular thickness(CMT),and central choroidal thickness(CCT)of patients with macular edema(ME)secondary to ischemic retinal vein occlusion(i RVO)following intravitreal Conbercept injection.METHODS:This retrospective study included 33 eyes from 33 patients who received intravitreal injections of Conbercept for ME secondary to i RVO.Treatments were performed on a 3+pro re nata(3+PRN)basis.All of the patients were examined by fundus fluorescein angiography and spectral domain optical coherence tomography at the first visit.Laser photocoagulation was performed in the nonperfusion area of the retina of all eyes after the first injection.BCVA,CMT,and CCT were observed before and after 6 mo of treatment.The number of injections necessary to achieve improved vision was also noted.RESULTS:Following Conbercept treatment,the mean BCVA significantly improved from 0.81±0.39 at baseline to 0.41±0.25 and 0.43±0.29 log MAR in the third and sixth months,respectively(both P=0.000).The CMT of the patients at baseline was 556.75±98.57μm;304.78±68.53 and 306.85±76.77μm 3 and 6 mo after treatment,respectively(both P=0.000 vs baseline).The CCTs of the patients at baseline,3 and 6 mo after treatment were 304.63±57.83,271.31±45.53,and 272.29±39.93μm,respectively(P=0.026 and 0.035 vs baseline).No severe adverse event relevant to the therapy was noted,and the average number of injections delivered was 3.35.CONCLUSION:Intravitreal Conbercept injection combined with laser photocoagulation appears to be a safe and effective treatment for ME secondary to i RVO in the short-term.

Intravitreal Bevacizumab with Grid Photocoagulation for Recurrent Macular Edema Secondary to Retinal Vein Occlusion

Purpose: To assess the efficacy of intravitreal bevacizumab (IVB) combined with grid photocoagulation in the management of recurrent macular edema secondary to retinal vein occlusion (RVO). Methods: This is a prospective, non-randomized, interventional study. Thirty five eyes with branch retinal vein occlusion (BRVO) and 15 eyes with central retinal vein occlusion (CRVO) were treated with grid photocoagulation combined with IVB for recurrent macular edema. The visual acuity, central macular thickness and intraocular pressure were outcome measures. The mean duration of follow-up was 18.1 ± 3.6 months. Results: One month after treatment, 45 of the 50 eyes showed complete resolution of the cystoid space. Compared with initial values, final central macular thickness was reduced significantly in both BRVO and CRVO groups (P < 0.001), but improvement in VA was significant only for eyes with BRVO (P = 0.012). The total number of IVB was 1.8 ± 0.3 for eyes with either BRVO or CRVO. Conclusion: IVB combined with grid photocoagulation is an effective treatment for reducing recurrent macular edema associated with RVO.

Sub-threshold micro-pulse diode laser treatment in diabetic macular edema： a Meta-analysis of randomized controlled trials

AIM：To examine possible differences in clinical outcomes between sub-threshold micro-pulse diode laser photocoagulation（SDM） and traditional modified Early Treatment Diabetic Retinopathy Study（mETDRS）treatment protocol in diabetic macuiar edema（DME）.METHODS：A comprehensive literature search using the Cochrane Collaboration methodology to identify RCTs comparing SDM with mETDRS for DME.The participants were type Ⅰ or type Ⅱ diabetes mellitus with clinically significant macuiar edema treated by SDM from previously reported randomized controlled trials（RCTs）.The primary outcome measures were the changes in the best corrected visual acuity（BCVA） and the central macuiar thickness（CMT） as measured by optical coherence tomography（OCT）.The secondary outcomes were the contrast sensitivity and the damages of the retina.RESULTS：Seven studies were identified and analyzed for comparing SDM（215 eyes） with mETDRS（210 eyes）for DME.There were no statistical differences in the BCVA after treatment between the SDM and mETDRS based on the follow-up：3mo（MD,-0.02;95% Cl,-0.12 to 0.09;P=0.77）,6mo（MD,-0.02;95% Cl,-0.12 to 0.09;P=0.75）,12mo（MD,-0.05;95% Cl,-0.17 to 0.07;P=0.40）.Likewise,there were no statistical differences in the CMT after treatment between the SDM and mETDRS in 3mo（MD,-9.92;95% Cl,-28.69 to 8.85;P=0.30）,6mo（MD,-11.37;95% Cl,-29.65 to 6.91;P=0.22）,12mo（MD,8.44;95% Cl,-29.89 to 46.77;P=0.67）.Three RCTs suggested that SDM laser results in good preservation of contrast sensitivity as mETDRS,in two different followup evaluations：3mo（MD,0.05;95% Cl,0 to 0.09;P=0.04） and 6mo（MD,0.02;95% Cl,-0.10 to 0.14;P=0.78）.Two RCTs showed that the SDM laser treatment did less retinal damage than that mETDRS did（OR,0.05;95% Cl,0.02 to 0.13;P〈0.01）.CONCLUSION：SDM laser photocoagulation shows an equally good effect on visual acuity,contrast sensitivity,and reduction of DME as compared to conventional mETDRS protocol with less retinal damage.

雷珠单抗联合激光光凝治疗视网膜静脉阻塞继发黄斑水肿患者的效果

目的探讨视网膜静脉阻塞(RVO)继发黄斑水肿(ME)患者采用雷珠单抗联合激光光凝治疗对视力的影响。方法选取2020年1月至2022年12月南昌市第一医院收治的84例(84只眼)RVO继发ME患者作为研究对象,按照随机数字表法分为对照组(42例)与观察组(42例),对照组采用激光光凝治疗,观察组采用雷珠单抗与激光光凝联合治疗。比较两组患者的最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)、眼压、血管内皮生长因子(VEGF)、眼底视网膜出血治疗效果及并发症。结果观察组治疗后的BCVA、CMT及VEGF低于对照组,眼底视网膜出血治疗总有效率(92.86%)高于对照组(76.19%),差异有统计学意义(P<0.05);两组患者治疗后的眼压比较,差异无统计学意义(P>0.05)。所有患者均未出现视网膜脱离、玻璃体积血及眼内感染等并发症,仅观察组出现1例一过性眼压升高。结论RVO继发ME患者采用雷珠单抗与激光光凝联合治疗有利于降低CMT、VEGF水平,改善患者的视力及眼底视网膜出血,且对患者眼压影响小,并发症并未增加,临床应用安全性高。

玻璃体腔注射抗VEGF与激光治疗对老年DME患者的影响

目的:探讨玻璃体腔注射抗血管内皮生长因子(VEGF)与激光治疗对老年糖尿病性黄斑水肿(DME)患者焦虑状况及生活质量的影响。方法:选取2021年6月1日~2022年6月1日接受治疗的91例DME患者,根据不同治疗方案分为对照组45例(45眼)和研究组46例(46眼),两组实施相同的护理方式,对照组实施视网膜格栅样光凝治疗,研究组实施玻璃体腔注射抗VEGF治疗;比较两组治疗前后最佳矫正视力(BCVA)、黄斑中心凹厚度(CFT)、焦虑状况[采用状态-特质焦虑量表(STAI)]及生活质量[采用中文版低视力者生活质量量表(CLVQOL)]。结果:治疗6个月后,两组BCVA、CFT、STAI评分均低于治疗前(P<0.05,P<0.01),且研究组低于对照组(P<0.01);治疗6个月后,两组CLVQOL评分高于治疗前(P<0.05,P<0.01),且研究组高于对照组(P<0.05,P<0.01)。结论:与单纯激光治疗相比,玻璃体腔注射抗VEGF治疗对老年DME患者具有良好疗效,可有效消退黄斑水肿、提高患者视力,有助于缓解患者焦虑情绪,从而提高患者生活质量。

常规药物联合视网膜激光光凝术治疗眼底病的临床效果研究

目的:探讨在眼底病治疗中应用常规药物联合视网膜激光光凝术的临床效果。方法:选取滨州沪滨爱尔眼科医院2023年5月—2024年5月收治的眼底病患者作为研究对象,共800例,随机分为参比组(常规药物治疗)和研究组(在参比组基础上实施视网膜激光光凝术治疗),每组400例。比较两组治疗效果、黄斑区视网膜厚度、中心凹容积、视功能。结果:研究组总有效率高于参比组(P=0.0001);治疗后,两组黄斑区视网膜厚度、中心凹容积升高,研究组高于参比组(P<0.05);治疗后,两组上方、下方、鼻侧、颞侧视神经纤维层厚度升高,研究组高于参比组(P<0.05);治疗后,两组视力、视野灰度水平降低,研究组低于参比组(P<0.05)。结论:常规药物联合视网膜激光光凝术在眼底病患者中的应用效果显著,能够改善患者的黄斑区视网膜厚度、中心凹容积及视神经纤维层厚度,提高视功能。

Progress in the Treatment of DME

Diabetic macular edema (DME) is a common ocular complication of diabetes mellitus (DM) and an important cause of vision loss. The pathogenesis of DME is complex and can occur at any time of diabetic retinopathy (DR). Effective methods of treating DME are essential to prevent irreversible damage to visual function. To date, laser photocoagulation, vascular endothelial growth factor (VEGF) inhibitors, and corticosteroids have demonstrated their therapeutic efficacy in large randomized controlled trials and real-life observational studies. Clinicians need to consider various factors, such as efficacy, safety, accessibility, and cost, in the selection of various options. This review summarizes the current therapeutic approaches for DME to provide new references for the treatment of DM.

Diabetic retinopathy:A review on its pathophysiology and novel treatment modalities

Diabetes mellitus(DM)is a chronic metabolic non-communicable disease with the ability to cause serious microvascular and macrovascular complications throughout the body,including in the eye.Diabetic retinopathy(DR),present in onethird of patients with diabetes,is a vision-threatening complication caused by uncontrolled diabetes,which greatly affects the retinal blood vessels and the lightsensitive inner retina,eventually leading to blindness.Several epidemiological studies elucidate that DR can vary by age of onset,duration,types of diabetes,and ethnicity.Recent studies show that the pathogenesis of diabetic retinopathy has spread its roots beyond merely being the result of hyperglycemia.The complexity of its etiopathology and diagnosis makes therapeutic intervention challenging.This review throws light on the pathological processes behind DR,the cascade of events that follow it,as well as the available and emerging treatment options.

康柏西普联合激光光凝对视网膜静脉阻塞伴黄斑水肿患者视力恢复及眼底荧光造影结果的影响

目的探讨康柏西普联合激光光凝在视网膜静脉阻塞(RVO)伴黄斑水肿患者中的应用价值。方法选取2020年1月至2022年1月丹江口市第一医院收治的102例RVO伴黄斑水肿患者作为研究对象,按照随机数字表法分为对照组与研究组,每组51例。对照组给予激光光凝治疗,研究组在对照组基础上加用康柏西普治疗,治疗后随访3个月。比较两组临床疗效、最佳矫正视力(BCVA)、黄斑中心视网膜厚度(CMT)、黄斑阈值敏感度(MTS)、眼底荧光造影(囊样渗透、弥漫渗透、局部渗透)及不良反应发生情况。结果研究组治疗总有效率为96.08%,高于对照组的82.35%,差异有统计学意义(P<0.05)。治疗后3个月,两组BCVA、MTS均高于治疗前,CMT均薄于治疗前,且研究组BCVA、MTS均高于对照组,CMT薄于对照组,差异有统计学意义(P<0.05)。研究组眼底荧光造影结果总发生率为3.92%,低于对照组的31.37%,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论康柏西普联合激光光凝治疗RVO伴黄斑水肿患者疗效确切,能消除黄斑水肿,提升MTS,减少视网膜渗透,改善患者视力,且安全可行,临床应用价值较高。

黄斑格栅样激光光凝联合玻璃体注射雷珠单抗、曲安奈德治疗视网膜静脉阻塞性黄斑水肿的效果及对视网膜血流参数的影响

目的探究黄斑格栅样激光光凝联合玻璃体注射雷珠单抗、曲安奈德治疗视网膜静脉阻塞性黄斑水肿的效果。方法选择2019年1月至2022年10月我院收治的300例视网膜静脉阻塞性黄斑水肿患者为研究对象,以随机数字表法将其分为对照组和观察组,各150例。对照组接受黄斑格栅样激光光凝+曲安奈德治疗,观察组在对照组基础上加施玻璃体注射雷珠单抗治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗3个月后,观察组的视网膜中央收缩期峰值流速(PSV)、舒张期峰值流速(EDV)高于对照组(P<0.05)。出院时,观察组的结缔组织生长因子(CTGF)、血小板源性生长因子-C(PDGF-C)及血管内皮生长因子(VEGF)水平低于对照组(P<0.05)。治疗3个月后,观察组的三叶草像差、总高阶像差、球差及彗差优于对照组(P<0.05)。结论黄斑格栅样激光光凝联合玻璃体注射雷珠单抗、曲安奈德治疗视网膜静脉阻塞性黄斑水肿效果满意,可调节生长因子表达,改善视网膜血流参数及视觉质量,值得推广。

抗血管内皮生长因子药物玻璃体腔注射联合激光光凝治疗重度非增殖性糖尿病视网膜病变伴黄斑水肿的临床研究

目的探究抗血管内皮生长因子药物玻璃体腔注射联合激光光凝治疗重度非增殖性糖尿病视网膜病变伴黄斑水肿的临床效果。方法前瞻性随机选取2020年3月—2023年3月因重度非增殖性糖尿病视网膜病变伴黄斑水肿在常熟市第一人民医院眼科门诊诊疗的80例患者进行研究,根据抛硬币法随机分为两组,各组40例,对照组予以全视网膜激光光凝治疗,观察组予以抗血管内皮生长因子药物玻璃体腔注射+全视网膜激光光凝治疗。比较整体临床疗效。结果观察组治疗总有效率高达95.00%,比对照组80.00%显著更高,差异有统计学意义(χ^(2)=4.114,P<0.05);观察组术后1、3、6个月的视力水平和黄斑中心视网膜厚度优于对照组,差异有统计学意义(P均<0.05);观察组术后并发症发生率12.50%和对照组20.00%比较,差异无统计学意义(P>0.05)。结论重度非增殖性糖尿病视网膜病变合并黄斑水肿患者采用玻璃体腔注射抗血管内皮生长因子+激光光凝治疗法,可发挥安全有效的治疗作用。

康柏西普联合视网膜激光治疗视网膜静脉阻塞继发黄斑水肿的疗效及对其睡眠的影响

目的:探究分析玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿的疗效及对其睡眠的影响。方法:选取2022年5月至2023年5月福建南安市医院眼科收治的视网膜分支静脉阻塞继发黄斑水肿患者86例作为研究对象,按照抛币法随机分为观察组和对照组,每组43例。对照组实施视网膜激光光凝治疗,观察组实施玻璃体腔注射康柏西普联合视网膜激光光凝治疗,比较2组患者的临床疗效、治疗前后最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)和睡眠质量。结果:1)观察组临床治疗总有效率高于对照组(P<0.05);2)观察组患者治疗后的BCVA高于对照组,CMT低于对照组(P<0.05);3)观察组治疗后的睡眠质量(PSQI)评分低于对照组(P<0.05)。结论:玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿可以获得较为理想的疗效,促进视力改善,还有助于提高睡眠质量,是一种切实有效的治疗方式,值得推广应用。

Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion

AIM：To compare changes in visual acuity and macular edema in patients with central retinal vein occlusion（CRVO）treated with intravitreal injections of bevacizumab,macular grid photocoagulation combined with pan retinal photocoagulation（PRP）,or both（bevacizumab＋grid＋PRP）.· METHODS：Our study is a retrospective cohort clinical study that examined patients that suffered from ischemic CRVO with macular edema.Study inclusion criteria were ischemic CRVO with macula edema and the availability of complete medical records for at least 12 mo after treatment.Excluded were patients with diabetes or any other retinal disease.We reviewed the medical records of patients treated in one ophthalmology departmentcomparing changes in visual acuity and macular edema in patients treated with intravitreal injections of bevacizumab vs those that were treated with macular grid photocoagulation and PRP or both.The main outcome measures were the differences in best corrected visual acuity（BCVA） and in macular thickness,as assessed by optical coherence tomography,between the enrollment and the final follow up visits.· RESULTS：Sixty-five patients met inclusion criteria.There were no statistically significant differences among the three groups in the mean changes in macular thickness as measured by ocular coherence tomography（131.5±41.2,108.6±29.2,and 121.1±121.1,P=0.110）,or in visual acuity（0.128±0.077,0.088±0.057,and 0.095±0.065）,for intravitreal injections,macular grid photocoagulation＋PRP and a combination of the treatments,respectively,P =0.111.The proportions of patients with macular edema after treatment were：26.1%,28.6%,and 14.3%,respectively,P=0.499.· CONCLUSION：Similar benefit was observed for intravitreal injections,laser photocoagulation,or a combined regimen in the treatment of CRVO.A nonstatistically significant trend for reduction in macular edema was observed following combined treatment.

Diabetic macular edema:New promising therapies

The treatment of diabetic macular edema is rapidly evolving.The era of laser therapy is being quickly replaced by an era of pharmacotherapy.Several pharmacotherapies have been recently developed for the treatment of retinal vascular diseases such as diabetic macular edema.Several intravitreal injections or sustained delivery devices have undergone phase 3 testing while others are currently being evaluated.The results of clinical trials have shown the superiority of some of these agents to laser therapy.However,with the availability of several of these newer agents,it may be difficult to individualize treatment options especially those patients respond differently to various therapies.As such,more effort is still needed in order to determine the best treatment regimen for a given patient.In this article,we briefly summarize the major new therapeutic additions for the treatment of diabetic macular edema and allude to some future promising therapies.

Novel strategies for the treatment of diabetic macular edema

Macular edema such as diabetic macular edema(DME) and diabetic retinopathy are devastating back-of-theeye retinal diseases leading to loss of vision. This area is receiving considerable medical attention. Posterior ocular diseases are challenging to treat due to complex ocular physiology and barrier properties. Major ocular barriers are static(corneal epithelium, corneal stroma, and blood-aqueous barrier) and dynamic barriers(bloodretinal barrier, conjunctival blood flow, lymph flow, and tear drainage). Moreover, metabolic barriers impede posterior ocular drug delivery and treatment. To overcome such barriers and treat back-of-the-eye diseases, several strategies have been recently developed which include vitreal drainage, laser photocoagulation and treatment with biologics and/or small molecule drugs. In this article, we have provided an overview of several emerging novel strategies including nanotechnology based drug delivery approach for posterior ocular drug delivery and treatment with an emphasis on DME.

玻璃体腔注射雷珠单抗联合视网膜激光光凝对视网膜静脉阻塞黄斑水肿的疗效及对脉络膜厚度和炎症因子的影响

目的:探究玻璃体腔注射雷珠单抗联合视网膜激光光凝对视网膜静脉阻塞(retinal vein occlusion,RVO)继发黄斑水肿(macular edema,ME)的疗效及对脉络膜厚度、炎症因子的影响。方法:选取2019年1月至2021年12月绵阳市第三人民医院收治的120例RVO-ME患者为研究对象,按乱数表法随机分为对照组与观察组,各60例。对照组予以视网膜激光光凝治疗,观察组予以玻璃体腔注射雷珠单抗联合视网膜激光光凝治疗。比较2组治疗前及治疗3、6个月时最佳矫正视力(best corrected visual acuity,BCVA)、黄斑区水肿容积、黄斑中心凹下脉络膜厚度(subfoveal choroidal thickness,SFCT)、房水中炎症因子[白细胞介素-6(interleukin-6,IL-6)、IL-8]水平;并比较2组并发症的发生情况。结果:观察组治疗3、6个月时的BCVA均明显优于对照组(均P<0.05)。观察组治疗3、6个月时的黄斑区水肿容积、SFCT及房水中IL-6、IL-8水平均明显低于对照组(均P<0.05)。2组并发症总发生率比较差异无统计学意义(分别为3.33%和1.67%,P>0.05)。结论:玻璃体腔注射雷珠单抗联合视网膜激光光凝可有效提高RVO-ME患者视力,缓解水肿症状,改善脉络膜厚度,降低房水中的炎症因子水平。

Treatment for diabetic macular oedema:looking further into the evidence

Throughout the years,people with diabetic macular oedema(DMO)have seen the number of options for their treatment increasing.Laser photocoagulation was the first of these and great experience is behind it;intraocular steroids followed and more recently anti-vascular endothelial growth factor(anti-VEGF)agents came to light.Ophthalmologists face now the dilemma of determining which may be the best therapeutic strategy for each particular patient based on best available evidence.This article summarises data available from randomised clinical trials(RCTs)on treatments for DMO and provides some facts about this condition and its treatments that need to be taken into consideration when treatment decisions are made.